Business Description
Cerevel Therapeutics Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US15678U1280
Share Class Description:
FRA:673: Ordinary SharesDescription
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.3 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.65 | |||||
| Debt-to-EBITDA | -0.83 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -8.3 | |||||
| 3-Year EPS without NRI Growth Rate | -10.7 | |||||
| 3-Year FCF Growth Rate | -4.8 | |||||
| 3-Year Book Growth Rate | 7.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -4.47 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 100 | |||||
| 12-1 Month Momentum % | -13.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.22 | |||||
| Quick Ratio | 10.22 | |||||
| Cash Ratio | 10.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -1.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -100.39 | |||||
| ROA % | -45.89 | |||||
| ROIC % | -258.74 | |||||
| ROC (Joel Greenblatt) % | -959.03 | |||||
| ROCE % | -48.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 14.49 | |||||
| Price-to-Tangible-Book | 14.48 | |||||
| EV-to-EBIT | -17.17 | |||||
| EV-to-EBITDA | -17.39 | |||||
| EV-to-FCF | -20.8 | |||||
| Price-to-Net-Current-Asset-Value | 27.44 | |||||
| Price-to-Net-Cash | 28.78 | |||||
| Earnings Yield (Greenblatt) % | -5.82 | |||||
| FCF Yield % | -4.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cerevel Therapeutics Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.522 | ||
| Beta | 0 | ||
| Volatility % | 22.91 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 23.6 | ||
| 12-1 Month Momentum % | -13.87 | ||
| 52-Week Range (€) | 20.6 - 27.4 | ||
| Shares Outstanding (Mil) | 182.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cerevel Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cerevel Therapeutics Holdings Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cerevel Therapeutics Holdings Inc Frequently Asked Questions
What is Cerevel Therapeutics Holdings Inc(FRA:673)'s stock price today?
The current price of FRA:673 is €23.60. The 52 week high of FRA:673 is €27.40 and 52 week low is €20.60.
When is next earnings date of Cerevel Therapeutics Holdings Inc(FRA:673)?
The next earnings date of Cerevel Therapeutics Holdings Inc(FRA:673) is 2025-02-03 Est..
Does Cerevel Therapeutics Holdings Inc(FRA:673) pay dividends? If so, how much?
Cerevel Therapeutics Holdings Inc(FRA:673) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers